Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bill for Law on IP Presented to Lower House
November 18, 2002
- Yamanouchi: Record-high Sales, Operating Profits Attributable to Harnal, Lipitor
November 18, 2002
- Drug Substitution by Pharmacists to Become Major Topic
November 18, 2002
- Eisai: Pariet, Aricept Contribute to Good Sales, Profits
November 18, 2002
- BUSINESS NEWS IN BRIEF
November 18, 2002
- Freund: Sales Up 1.9%, Operating Profits Down 41.2%
November 11, 2002
- GSK, Block Drug Company (Japan) Integrated on November 1
November 11, 2002
- Health Minister Determines to Set Up Better Healthcare System
November 11, 2002
- Kuraya Sanseido Takes Over OTC Business from Heisei Yakuhin
November 11, 2002
- Korosho to Prepare Comprehensive GL for Clinical Trials
November 11, 2002
- Council to Issue Supplements QC Verification Seals
November 11, 2002
- Dear-Doctor Letter for Edaravone Issued
November 11, 2002
- BD Places Great Importance on Social Contribution: President Cohen
November 11, 2002
- Revision of Precaution for 7 Drugs Including Famotidine Instructed
November 11, 2002
- Nippon Chemiphar to Comarket Allergy Test System with Wako Pure Chemical
November 11, 2002
- Package Insert for Estrogens to Be Revised
November 11, 2002
- Sankyo to Comarket Sysmex's Influenza Test Reagent
November 11, 2002
- Chuikyo Listens to Hospital Directors on DPC System
November 11, 2002
- Korosho to Gear Up Drafting of Medical Devices Industry Vision
November 11, 2002
- MEET THE LEADERS (10)
November 11, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…